

MOUD in the Criminal Justice Setting: Handoff and Transition of Care upon Release

The MetroHealth EXAM team

Dr. Joan Papp/Metro Health, Medical Director, Office of Opioid Safety

Associate Professor, Emergency Medicine CWRU/MetroHealth Campus

Objectives

Describe

Impact of the opioid epidemic on people who are involved with criminal justice settings

Contrast

The risk of adverse outcomes for an incarcerated person compared to the general population

List

Strategies to address outcomes for patients with OUD during incarceration

List

List strategies to ensure continuity of care after release from incarceration



The Opioid Crisis in the U.S.: *The 4 Waves*




Opioid Summaries by State

Drug overdose data comes from the CDC WONDER site. Available data is currently from 2018 with 2019 data usually being released in early 2021, at which time, these pages will be updated.

2018 Opioid-Involved Overdose Death Rates (per 100,000 people)¹





Prescripti on Opioids

1990s -2010 **Heroin** 2010-2015

Fentanyl 2015-19

POLYSUBSTA NCE Opioid + stimulants 2019- Current

In 2020, Ohio ranked 5th in the nation for overdose deaths with a rate of 47.2 overdose death/100k population

Sources:


- 1. Centers for Disease Control, Drug Overdose Death Rates by State, interactive web- based dashboard, accessed 9/8/2022
- 2. 2020 Ohio Drug Overdose Data: General Findings, Ohio Department of Health



2019-2020 U.S., Ohio and Cuyahoga County Overdose Fatalities

Overdose fatalities 30% nationally

2019–2020 Drug Overdose Death Rate Percent Change Map 2018-2019 Rate Increases Back to Drug Overdose Deaths



Drug Related Overdose Deaths.

235

2019

311

298

289

2021

Sources:

- 1. Centers for Disease Control, Drug Overdose Death Rates by State, interactive webbased dashboard, accessed 9/8/2022
- 2. 2020 Ohio Drug Overdose Data: General Findings, Ohio Department of Health
- 3. Cuyahoga County Board of Health, interactive web-based Overdose Data Dashboard accessed 9/8/2022



bv


fatalities

23%

How Do We Identify People At- Risk?

- Geographically state, zip code, address
- Demographics –
 age/gender/race/ethnicity
- Drugs used substances/route
- Personal Risk Factorscriminal justice history, medical or psych comorbidities, previous overdoses, other drugs used
- Access to healthcare SDOH

CCMEO Drug Related Overdose Deaths by Decedent Residence Zip Code



How Are People Who Use Drugs Affected by the Criminal Justice System?

77% of people who use heroin are involved with the criminal justice system

19 % of jail inmates report regularly using opioids

30-45 % of inmates report serious withdrawal or inability to control their use

15% 0f violent
offenders and 40 %
convicted of property
crimes report
committing offense to
support drug
addiction

Substance Abuse and Mental Health Services Administration: Use of Medication-Assisted Treatment for Opioid Use Disorder in Criminal Justice Settings. HHS Publication No. PEP19-MATUSECJS Rockville, MD: National Mental Health and Substance Use Policy Laboratory. Substance Abuse and Mental Health Services MetroHealth Administration, 2019.



What are the health Benefits of Providing Medications for Opioid Use Disorder (MOUD)?

Buprenorphine, Naltrexone and Methadone

- Decreased mortality
- Decreased transmission of infectious disease (HIV and HepC)
- Increased social functioning
- Increase in engagement in treatment

Untreated OUD leads to devastating health and social consequences which can be reduced with access to medication assisted treatment (MAT) with buprenorphine.

MOUD reduces monthly health care expenditures from \$223 to \$153 because patients are less than one half as likely to relapse



Criminal Justice and MOUD

MOUD SAVES MONEY

Every **\$1 invested in addiction** treatment yields a return of between \$4 and \$7 in reduced drug-related crime, criminal justice costs and theft alone.

When savings related to health care are included, total savings can exceed costs by a ratio of 12:1.

Treatment Research Institute, American Society of Addiction Medicine. (2013). FDA Approved Medications for the Treatment of Opiate Dependence: Literature Reviews on Effectiveness and Cost-Effectiveness. Philadelphia, PA: Treatment Research Institute. Available at http://www.asam.org/docs/default-source/advocacy/aaam_implications-for-opioid-addiction-treatment final.



MOUD is not widely available OUTSIDE the Criminal Justice Setting

- Less than half of substance use disorder programs offer MOUD and of those, only a third of the patients receive it
- Nearly all states report inadequate access to MOUD
- Barriers include DEA licensing (X waiver, insurance coverage, PA) other state requirements, lack of provider training and knowledge of treatments

MOUD Access in the Criminal Justice Setting is Even Worse....

Upon Reentry or Community Corrections



45%

of state and federal prisons in the U.S. referred inmates for methadone maintenance after release in 2009.32



of state and federal prisons in the U.S. provided referrals for community buprenorphine providers in 2009.32 Without MAT, there was a



from overdose within two weeks of release from prison in a 2018 study.²³



of persons with OUDs referred to treatment in 2014 by probation, parole or court authorities received methadone or buprenorphine compared to 41% referred by noncriminal justice sources.74



What Are the Risks of Criminal Justice Involvement for People Who Use Drugs?

75% of people with OUD relapse within 3 months

40-50% are rearrested for a new crime within 12 months

40 % increase in mortality following the first 2 weeks of release from incarceration

There will be institutions...

Judge Orders
OUD Med
Patients, the t



class MOI

Hure



FOR IMMEDIATE RELEASE

Friday, April 1, 2022

U.S. Attorney Rollins Announces Correctional Facilities Statewide to Maintain All Medications for Opioid Use Disorder

BOSTON – The U.S. Attorney's Office announced today that it has completed a review to ensure that state and county correctional facilities will maintain all medications used to treat Opioid Use Disorder (MOUD) for people already in treatment for Opioid Use Disorder (OUD) prior to entering a carceral facility's custody, as required by the Americans with Disabilities Act.

As part of its review, the U.S. Attorney's Office entered into a cooperative agreement with the Worcester County Sheriff's Office, sent letters of resolution to the Massachusetts Department of Correction as well as the Plymouth, Barnstable, Bristol, Berkshire and Dukes County Sheriff's Offices. The Essex and Suffolk County Sheriff's Offices were sent closing letters after their correctional facilities began providing, or secured contracts with medical vendors to provide, all three forms of MOUD.

Additionally, it should be noted that the Franklin County Sheriff's Office was the first correctional facility in the entire country to provide inmates access to all three FDA-approved forms of MOUD. The Hampden, Hampshire, Middlesex and Norfolk County Sheriff's Offices were early adopters in providing inmates access to MOUD, doing so even before the U.S. Attorney's Office began its review. Massachusetts also has one federal correctional facility, FMC Devens, which also provides access to all three forms of MOUD.

The U.S. Attorney's Office would like to acknowledge the Worcester County Sheriff's Office collaboration and partnership, marking the first agreement between the Department of Justice and a correctional facility regarding MOUD in the entire country. The Worcester, Plymouth and Dukes County Sherriff's Offices have implemented plans to provide all three medications before the end of 2022 and, in the meantime, will either transfer inmates to facilities that can provide the needed medications, or will otherwise facilitate maintaining the needed medications. All remaining correctional facilities in Massachusetts now provide access to all three forms of MOUD.

"Medications are a vitally important weapon in battling the opioid crisis, and our carceral facilities are on the front lines in that raging battle," said United States Attorney Rachael S. Rollins. "We commend the Sheriffs and the Massachusetts Department of Correction for working collaboratively with us. They collectively understood and welcomed the importance of this massive shift in thinking for corrections. I also want to specifically acknowledge the counties of Franklin, Hampden, Hampshire, Middlesex and Norfolk, for their early adoption of this crucial effort in our attempt to reduce opioid-related deaths. Their work, combined with our review and settlement distinguishes Massachusetts as one of the few states in the country in which every correctional facility at the state, local and federal level, is or will soon be, maintaining all forms of MOUD for inmates. This work saves lives. We are very grateful to our law enforcement partners running correctional facilities for their commitment and collaboration regarding providing the best treatment for the people in their custody and care."





Criminal Justice MOUD Goals

1. Identify all inmates with OUD

2. Treat withdrawal and initiate treatment during incarceration

3. Ensure treatment is continued after release

Program Components









1. Identify and Assess

Identification and administer level of care assessment to inmates with opioid use disorder (OUD)



2. Initiate treatment

Begin behavioral treatments, harm reduction education/naloxone training and addiction treatment medications



3. Collaborate and Secure

Collaborate with judges and court to secure an alternative to incarceration program pre-trial



4. Warm Hand-Off

Implement "warm hand-off," plan to connect inmate to ongoing care following release.



EXAM Team

CORE Team

- RN screening at intake, administer meds
- APRNS do medical assessment and order MOUD
- Counselors conduct LOC and provide behavioral treatment/groups

Supporting Team

Probation Officers

Bond Investigators

MH Informatics Staff

WRAP (Wellness, Recovery, Assessment, Placement)


TASC Program (Treatment Alternatives to Street Crime)





Screening at medical intake or after onset Referrals of from courts, withdrawal probation Self referral or 3rd party

1.) Identify and Assess




Identify inmates with SUD

Inmate with OUD identified



Referral placed for Medical and SUD/MH assessment


MOUD At Cuyahoga County Corrections





Share treatment Identify plan with treatment Judge facility Refer inmate to medical staff in the jail

2.) Collaborate and Secure



Collaborate with Court

Judges and probation officers educated on MOUD and treatment plan developed with both court and medical staff involvement

Medical staff implement treatment plan

Plan for post – release care



Release of Information



MU	LTIPARTY CONSENT FORM
- Noto	Name of Patient) authorize
(Name or general de	O Efam
to disclose to the sale	esignation of program making disdosure)
to disclose to: (the following persons or	organizations)
1. Cura hogo Cours 2. Osberton Sup 3. Ottomus	ty Common Pleas
the following Information:	Cecardo
I understand that my records are protecte Alcohol and Drug Abuse Patient Records, 4 consent unless otherwise provided for in ti consent at any time except to the extent the event this consent expires automatically as	d under the Federal regulations governing Confidentiality of 12 C.F.R. Part 2, and cannot be disclosed without my written he regulations. I also understand that I may revoke this hat action has been taken in reliance on it, and that in any follows:
(Specify the date, event, or condition upon which thi	s consent expires)
Date;	Signature of Participant
	Signature of parent guardian, or authorized representative, if required.




CONSENT FOR THE RELEASE OF CONFIDENTIAL ALCOHOL OR

Metal Silver	Patient)			_authori
(Name or general designation	n of program makina di	Inclasure)		
o disclose to the following person or organizat	ion:			
lame:				
ddress:				<u> </u>
ne following information: all C	condo	· · · · · ·		<u> </u>
	CENTO -			
	-	 		·
he purpose of the disclosure authorized hereir				
and anticonaire adulotized herein	15 to:	,		
			-	
	7			
FR) Part 2, and the Health Insurance Portabilities and 164, and carnot be disclosed without migulations. I also understand that I move that I	y and Accountability y written consent u	s, 42 Code of I Act of 1996 (Inless otherwit	Federal Regul HIPAA), 45 CF se provided fo	ations R, Parts or in the
understand that my alcohol and/or drug treatm evening Confidentiality of Alcohol and Drug Al FR) Part 2, and the Health Insurance Portability 60 and 164, and cannot be disclosed without m guilations. I also understand that I may revoke tion has been taken in reliance on it, and that I libws:	y and Accountability y written consent u	s, 42 Code of I Act of 1996 (Inless otherwit	Federal Regul HIPAA), 45 CF se provided fo	ations R, Parts or in the
FR) Part 2, and the Health Insurance by tag vision of the Health Insurance Portabilities on the Health Insurance Portabilities on the Health Insurance Without migulations. I also understand that I may revoke the has been taken in reliance on it, and that illows:	y and Accountability y written consent u this consent at any n any event this con	s, 42 Code of I Act of 1996 (Inless otherwit	Federal Regul HIPAA), 45 CF se provided fo	ations R, Parts or in the
FR) Part 2, and the Health Insurance by tag vision of the Health Insurance Portabilities on the Health Insurance Portabilities on the Health Insurance Without migulations. I also understand that I may revoke the has been taken in reliance on it, and that illows:	y and Accountability y written consent u this consent at any n any event this con	s, 42 Code of I Act of 1996 (Inless otherwit	Federal Regul HIPAA), 45 CF se provided fo	ations R, Parts or in the
FR) Part 2, and the Health Insurance Portability 0 and 164, and carnot be disclosed without iguistions. I also understand that I may revoke tion has been taken in reliance on it, and that llows:	y and Accountability y written consent u this consent at any n any event this con	s, 42 Code of I Act of 1996 (Inless otherwit	Federal Regul HIPAA), 45 CF se provided fo	ations R, Parts or in the
FR) Part 2, and the Health Insurance Portability 0 and 164, and carnot be disclosed without iguistions. I also understand that I may revoke tion has been taken in reliance on it, and that llows:	y and Accountability y written consent u this consent at any n any event this con	s, 42 Code of I y Act of 1996 (inless otherwis time except to nsent expires ;	Federal Regul HIPAA), 45 CF SE provided fo b the extent the Buttomatically	ations R, Parts or in the
FR) Part 2, and the Health insurance Portability 0 and 164, and carnot be disclosed without iguistions. I also understand that I may revoke the tion has been taken in reliance on it, and that lows:	y and Accountability y written consent u this consent at any n any event this con	s, 42 Code of i y Act of 1996 (inless otherwise time except to nsent expires in	Federal Regul HIPAA), 45 CF SE provided fo b the extent the Buttomatically	ations R, Parts or in the
FR) Part 2, and the Health insurance Portability 0 and 164, and carnot be disclosed without iguistions. I also understand that I may revoke the tion has been taken in reliance on it, and that lows:	y and Accountability y written consent at any in any event this con	s, 42 Code of i y Act of 1996 (inless otherwise time except to nsent expires in	Federal Regul HIPAA), 45 CF SE provided fo b the extent the Buttomatically	ations R, Parts or in the
FR) Part 2, and the Health Insurance Portability 0 and 164, and carnot be disclosed without in guistions. I also understand that I may revoke tion has been taken in reliance on it, and that illows:	y and Accountability y and Accountability y written consent at any in any event this con in expires) Signature of Part	s, 42 Code of i y Act of 1996 (inless otherwise time except to nsent expires a	Federal Regul HIPAAI, 45 CF See provided for the extent to automatically	ations R, Parts or in the hat as
FR) Part 2, and the Health Insurance Portability 50 and 164, and cannot be disclosed without in guistions. I also understand that I may revoke tion has been taken in reliance on it, and that in llows:	y and Accountability y written consent at any in any event this con	s, 42 Code of i y Act of 1996 (inless otherwith time except to nsent expires in icipant	Federal Regul HIPAAI, 45 CF See provided for the extent to automatically	ations R, Parts or in the hat as
FR) Part 2, and the Health Insurance Portabilities and 164, and cannot be disclosed without migulations. I also understand that I provide the control of the	y and Accountability y written consent at any y written consent at any in any event this con if expires) Signature of Part Signature of pare	s, 42 Code of i y Act of 1996 (inless otherwith time except to nsent expires in icipant	Federal Regul HIPAAI, 45 CF See provided for the extent to automatically	ntions R, Parts or in the hat as
FR) Part 2, and the Health Insurance Portability 50 and 164, and cannot be disclosed without in guistions. I also understand that I may revoke tion has been taken in reliance on it, and that in llows:	y and Accountability y written consent at any y written consent at any in any event this con if expires) Signature of Part Signature of pare	s, 42 Code of i y Act of 1996 (inless otherwith time except to nsent expires in icipant	Federal Regul HIPAAI, 45 CF See provided for the extent to automatically	ations R, Parts or in the hat as
FR) Part 2, and the Health Insurance Portability 50 and 164, and cannot be disclosed without in guistions. I also understand that I may revoke tion has been taken in reliance on it, and that in llows:	y and Accountability y written consent at any y written consent at any in any event this con if expires) Signature of Part Signature of pare	s, 42 Code of i y Act of 1996 (inless otherwith time except to nsent expires in icipant	Federal Regul HIPAAI, 45 CF See provided for the extent to automatically	ations R, Parts or in the hat as



Inmate Release date receives identified MOUD induction prior to release LISW/LICDC implements warm hand-off to treatment





- Connect to treatment facility
- Prescription for MOUD or appt for Vivitrol injection
- Take home Naloxone
- Follow up pamphlet provided
- MEC clinic walk in access to Buprenorphine provider/Behavioral health

MOUD starts while inmate is incarcerated



Inmate connected with ongoing care and engagement is tracked



Post Release- Continued support with Forensic Coordinators

Forensic Coordinators:

- Assist with appts
- Transportation
- Referrals
- Connect to providers for ongoing prescriptions

Peer Support

Case Management

Resources to support recovery and re- entry

Transportation to/from MOUD/IOP appts



Post Release Referrals



External	Referral	Date_	
----------	----------	-------	--

EXAM

Post Release Care Continuity Referral

-eritrisiacus	Г					
PROGRAMMATIC	First NameLast Name	AgeDOB//				
MMA	Race: White Black Am Indian Asian Multiracial Other	Ethnicity: Hispanic Non-Hispanic Gender: M F Trans				
OGRA	SO# GPRA Initial interview date:	GPRA 2 nd interview date:				
PR	Judge:Probation Officer:					
	Attorney: Charge(s)					
	TX Need: IOP IP PHP TBD MAT Need: Buprenorphine	Naltrexone Methadone LOC: Yes No Other				
	Registered Status: Yes No Prison Status:	PRESCREEN DATE:				
È	Date of initial contact: Type of contact:	F2f Phone Time spent with client: mins/hours				
COMMUN	Contact information.	Referral: Was client informed to contact External Forensic coordinator upon D/C for Continued MAT shot or nedication? Yes No				
	Release Date if known	Date client was informed:				
	External Peer Support Referral Completed? Yes No If yes, date	Employment:				
	Legal Needs: Yes No Housing Needs: Yes No	Source of Income?				
	Lyft required: Yes No	Employed: FT/PT SSDI SSI Zero income Other				
	Trauma Recovery Referral: Yes No If yes, date Other Needs:					
	Health Care Navigation: Primary Care Dentistry ID					
	History with an Opioid Use Disorder Provider?	Yes No				
8	If yes, Provider information? MetroHealth Recovery Resources					
ð	History of overdoses? Yes No Date of last drug use?					
	Drug(s) of Choice Any Mental Health Concerns					
	Suicidal History: Yes No					
	Was MAT administered? Yes No Type of MAT:	*				
	Date of medication induction: Narr					
	27					

Send Referrals to: Lisa Fair <u>Ifair@metrohealth.org</u> / Jaquetta Curlee <u>jcurlee@metrohealth.org</u>
AND
Scan into EPIC



Informational Pamphlet for Inmates

MetroHealth Treatment Provider Locations

MetroHealth

Parma Medical Center 12301 Snow Road Parma, Ohio 44130 Phone: (216) 524-7377

Hours of Operation:

Monday 7:30am- 8pm Tuesday-Friday 7:30am- 5:30pm

MetroHealth

Broadway Health Center 6835 Broadway Avenue Cleveland, Ohio 44105 Phone: (216) 957-1500

Hours of Operation:

Monday/ Wednesday/Friday 8am- 5pm Tuesday/Thursday 8am- 7pm

MetroHealth

Mobile MAT Clinic 2500 W 25th St. Cleveland, Ohio 44109 Phone: (216) 387-6290

Hours of Operation: Monday-Friday 10am-3pm

MetroHealth Walk-In MEC Clinic 2500 W 25th St. Cleveland, Ohio 44109 Phone: (216) 778-2051

Hours of Operation: Tuesday & Thursday 12:00pm-3pm For assistance with MAT and doctor's appointments Post release, please contact:

> Edward Lenzy elenzy@metrohealth.org 216-385-8035

Eric Sigmund APRN-CNP esigmund@metrohealth.org 216-633-6876







Medication Assisted Treatment for Opioid Use Disorder

Expanding Access to MAT in the Cuyahoga County Corrections Center

ExAM Program



Telehealth Prescriptions – Post Release

Telehealth prescriptions provided pending follow up

E prescribed (often after business hours)

Dedicated APRNs who will respond on weekends



Motivation and Engagement Clinic Short –Term Follow up

Provide walk – in one stop access to treatment

GOAL: Stabilize patients in early recovery by providing Walk- in access to MOUD, behavioral health treatments, basic healthcare, referrals to specialty care, support for social determinants of health

Pair provider visit for medication with behavioral treatment (group or individual)

Case management – assist with transportation, referrals, placement in treatment (transitions to primary care vs higher LOC)

Other: Naloxone kit distribution, vaccines, Peer support



Summary

Patients involved with
Criminal justice system
are THE HIGHEST RISK
patients we care for

Risk for mortality post release increased by up to 40 % in first 2 weeks post release

Risk can be reduced by providing MOUD during confinement and continuation post release

Vital to collaborate with courts/specialty dockets/probation officers to ensure working toward the same goal for each inmate

Addiction providers can provide support services
OUTSIDE the jail to ensure follow up and MOUD continuation





Questions?

